Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kennith Layton

Diagnostic Radiology Dallas, TX Medical Doctor

NPI 1194705301 CMS profile 145059

3500 Gaston Ave, Dallas, TX 75246

Open in the dashboard

General payments

$54,750

142 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$201,699 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Kennith Layton of Dallas, TX is reported in the CMS Open Payments database as having received $54,750 across 142 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $201,699 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,522 20
2024 General $9,432 16
2023 General $33,875 25
2022 General $8,380 39
2021 General $322 11
2020 General $577 7
2019 General $643 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kennith Layton
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Kennith Layton were reported at $1,522. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Kennith Layton Diagnostic Radiology median Middle half National median
2019 $643 $108 $29–$318 $163
2020 $577 $65 $21–$252 $114
2021 $322 $92 $24–$292 $132
2022 $8,380 $104 $29–$294 $149
2023 $33,875 $110 $29–$337 $160
2024 $9,432 $113 $30–$356 $164
2025 $1,522 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $30,640 41 payments
  2. Medtronic, Inc. $19,729 13 payments
  3. Bard Peripheral Vascular, Inc. $1,140 1 payment
  4. Imperative Care, INc $837 15 payments
  5. Medtronic USA, Inc. $504 12 payments
  6. Inari Medical, Inc. $484 20 payments
  7. DePuy Synthes Sales Inc. $433 10 payments
  8. Argon Medical Devices, Inc. $332 1 payment
  9. Balt USA, LLC $129 1 payment
  10. Penumbra, Inc. $128 11 payments
  11. Other $395 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $29,947 17 payments
  2. Acquisitions $19,361 1 payment
  3. Food and Beverage $4,048 118 payments
  4. Travel and Lodging $1,394 6 payments
Products named General payments · program years 2019–2025
  1. SPINEJACK Interventional Spine $14,979 18 payments
  2. AUTOPLEX $9,599 6 payments
  3. AVAFLEX $9,563 5 payments
  4. OPTABLATE $9,486 8 payments
  5. PCD $5,218 5 payments
  6. VERTEPORT $4,038 2 payments
  7. SPINEJACK Spine $898 2 payments
  8. MULTIGEN 2 $850 1 payment
  9. ZOOM 88-T LARGE DISTAL PLATFORM $514 10 payments
  10. CT THROMBECTOMY SYSTEM KIT $484 20 payments
  11. Other $3,657 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

16

Median for Diagnostic Radiology: 24

Drug cost

$157

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 16 $157

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$62,404

Medicare's payments for the services billed

Medicare patients

504

Average age 75

Services billed

840

284 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Chronic kidney disease 44%
Diabetes 42%
Ischemic heart disease 41%
Depression 41%
Heart failure 34%
Alzheimer's or dementia 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record